



## MK4 Bone Health Clinical Trials

Study	Design	Volunteers	MK4 Dose	Duration	Outcomes	Side Effects
Kodama and Okamoto, 2017; 39(10):846-850	Case series	n = 16; median age 56 years  13 volunteers also had epilepsy and were taking anticonvulsant medications	MK4 45 mg/day	12 months	<b>Bone laboratory markers:</b> MK4 improved laboratory markers associated with bone health.  <b>Bone density:</b> Bone density improved 5% after six months and 9% after twelve months.	Not reported
Shikano and Kineko 2016; 55(15):1997-2003	Prospective, observational study	n = 60 (21 men, 39 women); mean age 55 years.	MK4 45 mg/day or no MK4  All volunteers continued prednisone (30-60 mg/day) and all volunteers took bisphosphonate medications.	18 months	<b>Bone laboratory markers:</b> MK4 improved laboratory markers associated with bone health.  <b>Bone density:</b> Bone density was maintained in the MK4 group.  <b>Fractures:</b> MK4 maintained bone strength as indicated by zero fractures in people taking MK4 versus fractures in 5% of those not taking MK4.	Not reported



Study	Design	Volunteers	MK4 Dose	Duration	Outcomes	Side Effects
Huan and Wan 2015; 26(3): 1175-1186	Meta-analysis of 19 randomized, controlled clinical trials	n = 6759 postmenopausal women	45 mg/day or no MK4	Various	<b>Fractures:</b> MK4 maintained bone strength as indicated by a significant, 53% fewer fractures in women taking the MK4 compared to those not taking it.	Not reported
Jiang and Zhang 2014;9:121-7	Multicenter, randomized, double-blinded, double- dummy, noninferiority, positive-controlled clinical trial	n = 213 (all women); mean age 64 years.	MK4 group: 45 mg/day plus calcium 500 mg/day  Vitamin D2 (alfacalcidol) group: 0.5 micrograms (mcg)/day plus calcium 500 mg/day	12 months	<b>Bone laboratory markers:</b> MK4 improved laboratory markers associated with bone health.  <b>Bone density:</b> MK4 improved bone density 1.2% in the lumbar spine and 2.7% in the hip.  <b>Fractures:</b> Fractures were decreased in the MK4+calcium group compared to those taking just vitamin D2+calcium.	The researchers concluded that MK4 “was well tolerated and safe,” and that MK4 “is an effective and safe choice.”



Study	Design	Volunteers	MK4 Dose	Duration	Outcomes	Side Effects
Je and Joo 2011; 26(8): 1093-8	Randomized, controlled clinical trial	n = 78 (all women); mean age approx. 68 years	MK4 Group: MK4 45 mg/day, plus calcium 630 mg/day and vitamin D 400 IU/day  Control Group: Calcium 630 mg/day and vitamin D 400 IU/day	6 months	<b>Bone laboratory markers:</b> Improved lab markers associated with bone health in the MK4 group, but not in the control group.  <b>Bone density:</b> Bone density improved in the MK4 group, but did not improve in the control group.	Three people complained of a nausea sensation two times after taking MK4, but no other complaints were reported.
Shiraki and Itabashi 2009; 27(3):333-40	Randomized, prospective study	n = 109 (all women); mean age approx. 68 years	MK4 Group: 45 mg/day  Control Group: Calcium aspartate 1,200 mg/day (providing 133.8 mg elemental calcium)	6 months	<b>Bone laboratory markers:</b> Improved lab markers associated with bone health in the MK4 group, but not in the control group.	Minor, and no different than control group



Study	Design	Volunteers	MK4 Dose	Duration	Outcomes	Side Effects
Binkley and Harke 2009; 24(6):983-91	Double-blind, placebo-controlled	n = 381 (all women); mean age 62.5 years	MK4 45 mg/day or phylloquinone 1 mg/day orally or placebo	12 months	<b>Bone laboratory markers:</b> Improved lab markers associated with bone health.	None
Inoue and Fujita 2009; 27(1):66-75	Open-labeled	n = 4,378 (all women); mean age 68 years	MK4 45 mg/day alone or with calcium (1.2 to 3 grams) orally per day	48 months	<b>Fractures:</b> MK4 maintained strong bones as indicated by a decrease in fractures in people taking MK4+calcium.	Minor and statistically lower incidence in MK4 monotherapy group
Knapen and Schurgers 2007; 18(7): 963-972	Randomized, placebo-controlled	n = 325 (all women); mean age 66 years	45 mg/day or placebo	36 months	<b>Bone density:</b> Bone mineral content and bone strength improved in those those taking MK4.	Minor, and no different than placebo group



Study	Design	Volunteers	MK4 Dose	Duration	Outcomes	Side Effects
Cockayne and Adamson 2006;166(12):1256-1261	Meta-analysis of 13 randomized, controlled clinical trials		45 mg/day no MK4	Various	<b>Fractures:</b> Bone strength was maintained as indicated by a significant, 60% fewer vertebral fractures and 76% fewer nonvertebral fractures in people taking MK4 compared to those not taking MK4.	Not reported.
Knapen and Schurgers 2007; 18(7): 963–972	Randomized, placebo-controlled	n = 325 (all women); mean age 66 years	45 mg/day or placebo	36 months	<b>Bone density:</b> Bone mineral content and bone strength improved in those those taking MK4.	Minor, and no different than placebo group
Purwosunu and Muharram 2006; 32(2): 230-4	Double-blind, randomized, placebo-controlled	n = 63 (all women); mean age 60 years	MK4 group: MK4 45 mg/day plus calcium carbonate 1500 mg/day orally  Control group: placebo plus calcium carbonate 1500 mg/day orally	48 weeks	<b>Bone density:</b> MK4 increased bone density 1.74%, while those not taking MK4 lost bone density.	Two minor gastrointestinal symptoms, which subsided after temporarily stopping the MK4



Study	Design	Volunteers	MK4 Dose	Duration	Outcomes	Side Effects
Sasaki and Kusano 2005; 23(1):41-7	Randomized, controlled	n = 20 (12 men, 8 women), mean age 40 years	MK4 15 mg/day plus glucocorticoids (prednisone) or glucocorticoids without MK4	12 months	<b>Bone density:</b> MK4 supported healthy bone mineral density (BMD) while those not taking MK4 lost BMD.	None
Ochiai and Nakashima 2004; 34(3):579-83	Randomized, controlled	n = 33 (18 men, 15 women) mean age 65 years	MK4 45 mg/day or no MK4	12 months	<b>Bone laboratory markers:</b> MK4 improved lab markers associated with bone health.	Not reported
Yonemura and Fukasawa 2004; 43(1):53-60	Randomized, controlled	n = 60 (28 men, 32 women), mean age 32 years	Group A: control (glucocorticoids only) Group B:MK4 (45 mg/day) plus glucocorticoids Group C: vitamin D alone, plus glucocorticoids Group D: MK4 (45 mg/day) plus vitamin D and glucocorticoids	24 months	<b>Bone density:</b> Those taking just glucocorticoids lost BMD.  Those taking just vitamin D or vitamin D plus MK4 maintained bone density. Those taking only vitamin D, however, also had an increase in serum calcium, while serum calcium did not increase in those taking vitamin D plus MK4.	None



Study	Design	Volunteers	MK4 Dose	Duration	Outcomes	Side Effects
Nakashima and Yorioka 2004; 34(3):579-83	Randomized, noncontrolled	n = 32 hemodialysis patients (19 men and 13 women) with low parathyroid hormone (PTH); mean age 58 years	MK4 45 mg/day	12 months	<b>Bone laboratory markers:</b> MK4 improved bone laboratory markers (eg, undercarboxylated osteocalcin) associated with bone health.	None
Iketani and Kiriike 2003; 117(3): 259-69	Controlled	n = 39 (all women); mean age 22 years	MK4 45 mg/day or no MK4	11 months	<b>Bone density:</b> MK4 supported healthy bone density compared with those not receiving MK4.	None
Shiomi and Nishiguchi 2002: 97(4): 978-81	Randomized, controlled	n = 50 (all women); mean age 60 years	MK4 45 mg/day or no MK4	24 months	<b>Bone density:</b> MK4 preserved bone density compared with those not taking MK4.	None



Study	Design	Volunteers	MK4 Dose	Duration	Outcomes	Side Effects
Ushiroyama and Ikeda 2002;41 (3):211-21	Randomized, controlled	n = 172 (all women); mean age 53 years	Group A: MK4 45 mg/day Group B: vitamin D3 1 µg/day Group C: MK4 plus vitamin D3 Group D: Control group	24 months	<b>Bone density:</b> MK4+Vitamin D increased bone density nearly 5% while those taking MK4 alone had a 0.14% increase in bone density.	None
Bunyaratavej and Penkitti 2001;84 Suppl 2:S553-9	Randomized, controlled	n = 83 (all women)	MK4 group: MK4 45 mg/day plus calcium 800 mg/day Control group: calcium 800 mg/day	12 months	<b>Bone laboratory markers:</b> MK4 Improved lab markers associated with bone health compared to those taking calcium alone.  <b>Bone density:</b> MK4 improved bone density compared to those taking calcium alone.	Two cases of mild skin rash that subsided upon discontinuation of MK4



Study	Design	Volunteers	MK4 Dose	Duration	Outcomes	Side Effects
Inoue and Sugiyama 2001; 48(1):11-8	Randomized, controlled	n = 18 (5 boys, 13 girls), ages 4 to 14 years	Group A: MK4 (2 mg/kg/day) plus glucocorticoid  Group B: MK4 (2 mg/kg/day) plus Vitamin D (0.03 µg/kg/day) and glucocorticoid	12 weeks	<b>Bone density:</b> MK4 maintained bone density while those not taking MK4 lost bone density.	None
Nishiguchi and Shimoi 2001;35 (4):543-5	Randomized, controlled	n = 30 (all women); mean age 55 years	MK4 45 mg/day orally or no MK4	24 months	<b>Bone density:</b> MK4 increased bone density by 0.3%, while those not taking MK4 lost 3.5%.	None
Iwamoto and Takeda 2000; 5(6):546-51	Randomized	n = 92 (all women); mean age 64 years	Group A: vitamin D3 0.75 µg/day  Group B: MK4 45 mg/day  Group C: MK4 plus vitamin D3  Group D: calcium lactate 2000 mg /day	24 months	<b>Bone density:</b> MK4 plus Vitamin D increased bone density compared to all other groups.	None



Study	Design	Volunteers	MK4 Dose	Duration	Outcomes	Side Effects
Yonemura and Kimura 2000; 66(2):123-8	Randomized, controlled	n = 20 (14 men, 16 women), mean age 28 years	Group A: Prednisolone Group B: MK4 (45 mg/day) orally plus prednisolone	10 weeks	<b>Bone density:</b> MK4 maintained bone density while those not taking MK4 lost bone density.	None
Somekawa and Chigughi 1999; 84(8):2700-4	Randomized, controlled	n = 110 (all women); mean age 46.2 years	Group A: leuprolide (Lupron, Eligard) Group B: leuprolide plus MK4 45 mg/day Group C: leuprolide plus vitamin D3 0.5 µg/day Group D: leuprolide plus MK4 and vitamin D3	6 months	<b>Bone density:</b> MK4 supported healthy bone density.	Not reported



Study	Design	Volunteers	MK4 Dose	Duration	Outcomes	Side Effects
Shiraki and Shiraki 2000; 15(3):515-21	Randomized, open-label, controlled	n = 2411 women; mean age 67 years	Group A: MK4 45 mg/day plus calcium 150 mg/day  Group B: calcium 150 mg/day	24 months	<b>Bone density:</b> MK4 maintained bone density compared to those not taking MK4.  <b>Fractures:</b> MK4 maintained strong bones as indicated by 60% fewer fractures in the group taking MK4 compared with the calcium-only group.	Not reported
Iwamoto and Kosha 1999; 31(2):161-4	Randomized, controlled	n = 72 women	Group A: no intervention control  Group B: conjugated equine estrogen 0.625 mg/day and medroxyprogesterone 2.5 mg/day  Group C: vitamin D3 1000 mg/day  Group D: MK4 45 mg/day	12 months	<b>Bone density:</b> MK4 increased bone density while bone density decreased in the control group.	Not reported



DELIVERING HEALTH

Study	Design	Volunteers	MK4 Dose	Duration	Outcomes	Side Effects
Sugiyama and Tanaka 1999; 14(8):1466-7	Case report	n = 1 (girl); age 8 years	MK4 2 mg/kg/day and vitamin D3 0.05 µg/kg/day	15 months	<b>Bone density:</b> MK4 plus vitamin D increased bone density.	None
Nagasawa and Fujii 1998; 351(9104):724	Case series	n = 17 (8 men, 9 women); ages 36-70 years with chronic kidney failure on dialysis	MK4 45 mg/day	1 year	<b>Total Cholesterol:</b> MK4 promoted healthy cholesterol levels.	Not reported



## MK4 Laboratory Studies

Molecular Effect	Benefit	Studies
Binds to the steroid and xenobiotic receptor (SXR)/pregnane X receptor (PXR)	By binding to these receptors, MK4 activates genes that promote the creation of osteoblasts, which build new bone.	Ichikawa T, Horie-Inoue K, Ikeda K, et al. 2006; 281(25):16927-16934. Igarashi M, Yogiashi Y, Mihara M, et al.. 2007; 27(22):7947-7954. Tabb MM, Sun A, Zhou C, et al. 2003;278(45): 43919-43927.
Inhibits NF-kB	NF-kB helps regulate inflammation. Elevated levels of NF-kB are associated with increased inflammation, which in turn stimulates the production of osteoclasts. It also helps osteoclasts stay alive longer, giving them more time to destroy bone. Healthy inflammation balance is important for maintaining strong bones.	Ichikawa T, Horie-Inoue K, Ikeda K 2006; 281 (25):16927-16934. Ide Y, Zhang H, Hamajima H, et al. 2009; 22(3): 599-604. Ozaki I, Zhang H, Mizuta T, et al. 2007;13(7): 2236-45. Yamaguchi M, Weitzmann MN. 2011;27(1): 3-14.
Reduces RANKL activity	RANKL is a cellular receptor that's involved in bone health. Increased RANKL activity damages bone. MK4 reduces RANKL activity, which is associated with improved bone health.	Wu WJ, Kim MS, Ahn BY. 2015;6(10):3351-3358.



Molecular Effect	Benefit	Studies
Activates the following genes: growth differentiation factor 15 (GDF15), Stanniocalcin, Tenascin-c and bone morphogenic protein-2 (BMP-2).	These genes are involved in promoting healthy bone collagen. Collagen is crucial for bone health and strength.	Akbari S, Rasouli-Ghahroudi AA. 2018; 2018:4629383. Ichikawa T, Horie-Inoue K, Ikeda K, et al. 2006; 281(25):16927-16934. Ichikawa T, Horie-Inoue K, Ikeda K, et al. 2007; 39(4):239-247.
Increases calcium binding to bone.	MK4 enhances the ability of vitamin D to add calcium to bone.	Miyake N, Hoshi K, Sano Y, et al. 2001;12(8): 680-687.
Supports healthy bone marrow stem cell production.	MK4 supports bone stem cell health, which is important for the creation of healthy red blood cells, white blood cells and platelets.	Fujishiro A, Iwasa M, Fujii S, et al. 2020;112(3): 316-330.
Inhibits matrix metalloproteinase (MMP).	MMP plays a key role in regulating the immune system, and lowering MMP activity is associated with improved immune health and healthy cell structure.	Ide Y, Zhang H, Hamajima H, et al. 2009; 22(3): 599-604. Naim A, Pan Q, Baig MS. 2017;7(4):367-372.



Molecular Effect	Benefit	Studies
Decreases serum alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP).	Decreasing these blood proteins is associated with cellular health and healthy cell division.	Nouso, K, Uematsu S, Shiraga K, et al. 2005; 11(42):6722-6724.
Increases caspase-3.	Caspase-3 helps regulate the lifecycle of cells. Caspase-3 is associated with healthier cells.	Miyazawa K, Yaguchi M, Gotoh A, et al. 2001 Jul;15(7):1111-7. Nishimaki J, Miyazawa K, Yaguchi M, et al. 1999 Sep;13(9):1399-405.
Increases protein kinase A (PKA).	PKA is involved in regulating glycogen, sugar and lipid metabolism.	Otsuka M, Kato N, Shao R-X, et al. 2004; 40(1):243-51.
Decreases cyclin D1.	Cyclin D1 is involved in regulating the lifecycle of cells. Decreasing cyclin D1 is associated with healthier cells.	Ozaki I, Zhang H, Mizuta T, et al. 2007;13(7): 2236-45.